Arcutis Biotherapeutics Gestione
Gestione criteri di controllo 2/4
Arcutis Biotherapeutics Il CEO è Frank Watanabe, nominato in Jan2016, e ha un mandato di 8.83 anni. la retribuzione annua totale è $ 4.94M, composta da 12.8% di stipendio e 87.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.56% delle azioni della società, per un valore di $ 6.67M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.8 anni e 4.3 anni.
Informazioni chiave
Frank Watanabe
Amministratore delegato
US$4.9m
Compenso totale
| Percentuale dello stipendio del CEO | 12.8% |
| Mandato del CEO | 8.8yrs |
| Proprietà del CEO | 0.6% |
| Durata media del management | 2.8yrs |
| Durata media del Consiglio di amministrazione | 4.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Nov 15Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry
Sep 23
Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely
Aug 22Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Jul 17Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing
Jun 21Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
May 24Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory
May 20Arcutis Biotherapeutics: Betting Big On Zoryve
May 01New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Apr 25Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues
Mar 03Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates
Mar 02Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up
Feb 28Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
Jan 31Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%
Oct 23Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
Aug 13Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57
Aug 11Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?
May 02Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$196m |
| Jun 30 2024 | n/a | n/a | -US$199m |
| Mar 31 2024 | n/a | n/a | -US$217m |
| Dec 31 2023 | US$5m | US$634k | -US$262m |
| Sep 30 2023 | n/a | n/a | -US$268m |
| Jun 30 2023 | n/a | n/a | -US$331m |
| Mar 31 2023 | n/a | n/a | -US$327m |
| Dec 31 2022 | US$5m | US$590k | -US$311m |
| Sep 30 2022 | n/a | n/a | -US$311m |
| Jun 30 2022 | n/a | n/a | -US$260m |
| Mar 31 2022 | n/a | n/a | -US$235m |
| Dec 31 2021 | US$4m | US$525k | -US$206m |
| Sep 30 2021 | n/a | n/a | -US$169m |
| Jun 30 2021 | n/a | n/a | -US$150m |
| Mar 31 2021 | n/a | n/a | -US$144m |
| Dec 31 2020 | US$3m | US$442k | -US$136m |
| Sep 30 2020 | n/a | n/a | -US$114m |
| Jun 30 2020 | n/a | n/a | -US$90m |
| Mar 31 2020 | n/a | n/a | -US$63m |
| Dec 31 2019 | US$1m | US$390k | -US$42m |
| Sep 30 2019 | n/a | n/a | -US$35m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | US$634k | US$327k | -US$19m |
Compensazione vs Mercato: La retribuzione totale di Frank ($USD 4.94M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.17M ).
Compensazione vs guadagni: La retribuzione di Frank è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Frank Watanabe (56 yo)
8.8yrs
Mandato
US$4,935,266
Compensazione
Mr. Todd Franklin Watanabe, also known as Frank, M.A., serves as Director of Amunix Pharmaceuticals, Inc. since June 2021. He has been President of Arcutis Biotherapeutics, Inc. (Formerly known as Arcutis...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 8.8yrs | US$4.94m | 0.56% $ 6.7m | |
| Co-Founder & Independent Director | no data | US$153.74k | 0.77% $ 9.1m | |
| Senior VP & Chief Medical Officer | 4.3yrs | US$1.67m | 0.11% $ 1.3m | |
| Senior VP & Chief Commercial Officer | 1.2yrs | US$2.03m | Nessun dato | |
| Senior VP & Chief Financial Officer | less than a year | Nessun dato | 0.041% $ 490.5k | |
| Chief Digital & Technology Officer | 3.1yrs | Nessun dato | Nessun dato | |
| Vice President of Finance & Corporate Controller | no data | Nessun dato | Nessun dato | |
| VP and Chief Compliance Officer & Privacy Officer | 3.8yrs | Nessun dato | Nessun dato | |
| Senior VP | 2.8yrs | US$5.14m | 0.043% $ 510.3k | |
| Head of Corporate Communications | 3.3yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Market Access | 1.4yrs | Nessun dato | Nessun dato | |
| Vice President of Sales | 1.8yrs | Nessun dato | Nessun dato |
2.8yrs
Durata media
56yo
Età media
Gestione esperta: Il team dirigenziale di ARQT è considerato esperto (durata media dell'incarico 2.8 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 7.8yrs | US$4.94m | 0.56% $ 6.7m | |
| Co-Founder & Independent Director | 8.6yrs | US$153.74k | 0.77% $ 9.1m | |
| Board Member | 8.6yrs | US$181.24k | 0.028% $ 328.3k | |
| Scientific Advisor | no data | Nessun dato | Nessun dato | |
| Scientific Advisor | no data | Nessun dato | Nessun dato | |
| Scientific Advisor | no data | Nessun dato | Nessun dato | |
| Independent Chairman of the Board | 3.2yrs | US$146.24k | 0.0089% $ 105.9k | |
| Independent Director | 4yrs | US$148.74k | 0% $ 0 | |
| Director | 4.3yrs | US$144.24k | 0.14% $ 1.6m | |
| Independent Director | 3.4yrs | US$163.74k | 0.0077% $ 91.1k | |
| Scientific Advisor | no data | Nessun dato | Nessun dato | |
| Scientific Advisor | no data | Nessun dato | Nessun dato |
4.3yrs
Durata media
63.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ARQT sono considerati esperti (durata media dell'incarico 4.3 anni).